Hostname: page-component-7c8c6479df-8mjnm Total loading time: 0 Render date: 2024-03-29T11:01:11.467Z Has data issue: false hasContentIssue false

Could COVID-19 represent a negative prognostic factor in patients with stroke?

Published online by Cambridge University Press:  20 April 2020

Antonio Siniscalchi*
Affiliation:
Department of Neurology and Stroke Unit, Annunziata Hospital of Cosenza, Cosenza, Italy
Luca Gallelli
Affiliation:
Department of Health Science, School of Medicine, University of Catanzaro, Catanzaro, Italy Clinical Pharmacology Unit, Mater Domini University Hospital, Catanzaro, Italy
*
Author for correspondence: Antonio Siniscalchi, E-mail: anto.siniscalchi@libero.it
Rights & Permissions [Opens in a new window]

Abstract

Type
Letter to the Editor
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved.

To the Editor—Coronavirus infectious disease 2019 (COVID-19) is a highly contagious disease that has become a worldwide pandemic. Coronaviruses (CoVs), positive-stranded RNA viruses, are known to cause respiratory or intestinal infections in humans and animals.Reference Jin, Hong, Chen and Zhou1 Coronaviruses are known to affect the cardiovascular system.Reference Madjid, Safavi-Naeini, Solomon and Vardeny2

The SARS-CoV-2 virus uses the enzyme 2 receptor (ACE2) to gain entry into cells,Reference Baig, Khaleeq, Ali and Syeda3 and these receptors have been revealed in the neuronal and glial cells of the human brain. Thus, they may be a potential target of SARS-CoV-2, which might explain the death of olfactory cells in patients with COVID-19.Reference Jin, Hong, Chen and Zhou1 CoVs can enter the central nervous system through 2 distinct pathways: retrograde neuronal diffusion or hematogenous diffusion. The spread of SARS-CoV-2 through the cribriform plaque of the ethmoid bone during an initial or subsequent infection phase can lead to brain involvement. In the systemic circulation, the presence of ACE2 receptors on both capillary and neuronal endothelial cells could be responsible for the subsequent spread and damage to the cerebral nervous system without substantial inflammation. The presence of CoVs in the cerebral nervous system has been confirmed in the cerebrospinal fluid and brain tissues of patients during autopsies.Reference Lau, Yu and Chu4,Reference Xu, Zhong and Liu5

Several symptoms indicative of CNS involvement are present in approximately one-third of COVID-19 patients: dizziness, headache, impaired consciousness, ataxia, epilepsy, and acute cerebrovascular disease.Reference Jin, Hong, Chen and Zhou1 Changes in the coagulation system (ie, D-dimer and platelet abnormalities)Reference Madjid, Safavi-Naeini, Solomon and Vardeny2,Reference Tang, Bai, Chen, Gong, Li and Sun6 and in inflammatory biomarkers (eg, interleukin-6, C-reactive protein, and ferritin)Reference Ruan, Yang and Wang7 have been reported in COVID-19 patients. In patients with stroke, the presence of COVID-19 could be a potential extrinsic factor in the genesis or worsening of stroke. Infection or high levels of proinflammatory biomarkers indicate significantly increased risk of ischemic stroke, especially in the elderly.Reference Consoli, Vidale and Aguglia8-Reference Siniscalchi, Gallelli and Malferrari10 The onset or worsening of a stroke in these patients could be caused either by direct damage of the CoVs on the nervous system and/or by an activation of the mechanisms of COVID-19 inflammation induced as well coagulation disorders. As the disease spreads and new evidence emerges, we need to identify the existence of additional pathophysiological mechanisms of stroke in COVID-19 patients. We should establish a prospective registry of these patients to better identify the factors most responsible for a possible greater onset or worse prognosis of stroke in these patients and to identify and/or predict a better or lesser response of these patients to thrombolytic treatments.

Acknowledgments

Antonio Siniscalchi serves as national member for the Italian National Society of Neurovascular Disease (SINV).

Financial support

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest

All authors state that they have no conflict of interest regarding this study.

References

Jin, H, Hong, C, Chen, S, Zhou, Y, et al.Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. Stroke Vasc Neurol 2020 April 1 [Epub ahead of print]. doi: 10.1136/svn-2020-000382.CrossRefGoogle ScholarPubMed
Madjid, M, Safavi-Naeini, P, Solomon, SD, Vardeny, O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol 2020 Mar 27 [Epub ahead of print]. doi: 10.1001/jamacardio.2020.1286.CrossRefGoogle ScholarPubMed
Baig, AM, Khaleeq, A, Ali, U, Syeda, H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 2020;11:995998.CrossRefGoogle ScholarPubMed
Lau, KK, Yu, WC, Chu, CM, et al.Possible central nervous system infection by SARS coronavirus. Emerg Infect Dis 2004;10:342344.10.3201/eid1002.030638CrossRefGoogle ScholarPubMed
Xu, J, Zhong, S, Liu, J, et al.Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine Mig in pathogenesis. Clin Infect Dis 2005;41:10891096.10.1086/444461CrossRefGoogle ScholarPubMed
Tang, N, Bai, H, Chen, X, Gong, J, Li, D, Sun, Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 Mar 27 [Epub ahead of print]. doi: 10.1111/jth.14817.Google ScholarPubMed
Ruan, Q, Yang, K, Wang, W, et al.Clinical predictors of mortality due to COVID-19 based on analysis of data o f 150 patients from Wuhan, China. Intensive Care Med 2020 Mar 3 [Epub ahead of print]. doi: 10.1007/s00134-020-05991-x.Google Scholar
Consoli, D, Vidale, S, Aguglia, U, et al.Previous infection and the risk of ischaemic stroke in Italy: the IN2 study. Eur J Neurol 2015;22:514519.CrossRefGoogle ScholarPubMed
Siniscalchi, A, Iannacchero, R, Anticoli, S, et al.Anti-inflammatory strategies in stroke: a potential therapeutic target. Curr Vasc Pharmacol 2016;14:98105.10.2174/1570161113666150923111329CrossRefGoogle ScholarPubMed
Siniscalchi, A, Gallelli, L, Malferrari, G, et al.Cerebral stroke injury: the role of cytokines and brain inflammation. J Basic Clin Physiol Pharmacol 2014;25:131137.10.1515/jbcpp-2013-0121CrossRefGoogle ScholarPubMed